Overall, these data indicate that iberdomide mediated degradation of Ikaros and Aiolos regulates key genes and pathways relevant for aberrant plasmablast differentiation during SLE pathogenesis. This evidence concerns the gene IKZF1 and systemic lupus erythematosus.